Dr. David Collingridge, Editor-in-Chief & Publisher, The Lancet Oncology, London, UK; Clinical Associate Professor, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.
Dr. David Collingridge has been Editor-in-Chief of The Lancet Oncology (Impact Factor, 25·12) since March, 2002, after 6 months in the role of Senior Editor. Prior to his appointments at The Lancet Oncology, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
Dr. Collingridge has published numerous peer-review articles, editorials, opinion pieces, and news reports, and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine, at Hofstra North Shore-LIJ School of Medicine in the USA.